Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLOE4-LTE: Long-term Extension of ALZ-801 in Early Alzheimer's Disease
NCT06304883Phase 3Terminated
- Sponsor
- Alzheon, Inc.
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of valiltramiprosate in Alzheimer's disease (AD), sponsored by Alzheon, Inc.. Started Apr 2024; status: terminated.
02
Drugs
valiltramiprosate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06304883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304883.